Monga Varun, Mani Hariharasudan, Hirbe Angela, Milhem Mohammed
Division of Oncology, Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA.
Division of General Medicine, Department of Medicine, University of Iowa, Iowa City, IA 52242, USA.
Cancers (Basel). 2020 Jul 19;12(7):1962. doi: 10.3390/cancers12071962.
Chondrosarcomas are the most common malignant tumors of the cartilage, are seen predominantly in adults, and have varied clinical behavior. The majority of them affect the medullary canal of long bones and pelvic bones. The prognosis of chondrosarcoma is closely related to histological grading; however, the grading is subject to interobserver variability. Conventional chondrosarcomas are overall considered to be chemotherapy- and radiation-resistant, resulting in limited treatment options. The majority of advanced conventional chondrosarcomas are treated with chemotherapy without any survival benefit. Recent studies have evaluated molecular genetic findings which have improved the understanding of chondrosarcoma biology. Newer therapeutic targets are desperately needed. In this review article, we explore ongoing clinical trials evaluating novel ways of treating advanced conventional chondrosarcoma.
软骨肉瘤是最常见的软骨恶性肿瘤,主要见于成年人,临床行为多样。其中大多数累及长骨和骨盆的髓腔。软骨肉瘤的预后与组织学分级密切相关;然而,分级存在观察者间差异。传统软骨肉瘤总体上被认为对化疗和放疗耐药,导致治疗选择有限。大多数晚期传统软骨肉瘤接受化疗,但无生存获益。最近的研究评估了分子遗传学发现,这增进了对软骨肉瘤生物学的理解。迫切需要新的治疗靶点。在这篇综述文章中,我们探讨了正在进行的评估晚期传统软骨肉瘤新治疗方法的临床试验。